We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
The rise in type 2 diabetes has sparked a variety of treatment options, including glucagon-like peptide-1 (GLP-1) receptor agonists. GLP-1s are a class of injected drugs (additional oral options are currently in development) that “mimic the action of GLP-1 and increase the incretin effect in patients with type 2 diabetes, stimulating the release of insulin.”1 Commonly used when oral treatment alone is not enough, the benefits of GLP-1s include a reduction of glucagon and glycosylated haemoglobin (HbA1c), weight loss and a low risk of hypoglycemia.2
Current GLP-1 receptor agonists include liraglutide, dulaglutide and exenatide. These long-acting GLP-1s are generally well tolerated by patients, and may be taken once daily or weekly.3 Various GLP-1s are proving to have other therapeutic benefits, such as cardiovascular health, weight loss and more.4 Market leaders include Novo Nordisk’s Victoza, and Lilly’s Trulicity.5
As injectable products, GLP-1s are commonly delivered using insulin pens or auto-injectors. When taken in combination with oral therapies, the GLP-1 class may help to stave off the onset of insulin-dependent diabetes. There are also other interesting combination drugs in development with GLP-1s – including combinations with insulin (some are already on the market) or with glucagon. Oral GLP-1 drugs, e.g. Novo Nordisk’s semaglutide in Phase III development, are also demonstrating positive results. 6
West currently partners with customers to develop and manufacture containment and delivery solutions for this class of drug. From primary containment options, including vials, cartridges and pre-fillable syringes, to delivery systems and contract manufacturing of glucose monitoring systems, West supports the delivery of diabetes care to more than 60 million diabetes patients every day.
To learn more about how West can help, contact us today.
Each year, on November 14, World Diabetes Day (WDD) is recognized around the world. WDD was created in 1991 in response to growing concerns about the escalating health threat posed by diabetes. It is the world’s largest diabetes awareness campaign, reaching a global audience of over 1 billion people in more than 160 countries.
On November 14, World Diabetes Day will be observed around the globe. Diabetes is a growing issue, with more than 415 million adults living with the disease, a number that is expected to increase to 642 million – or 1 in 10 adults – by 2040.
When left untreated, diabetes eventually can lead to a variety of issues for patients, including complications such as stroke, blindness and heart and/or kidney disease. In addition, adherence to painful or inconvenient injection treatments can be difficult for patients, with as many at 57% of Type 1 and Type 2 diabetes patients admitting to intentionally skipping injections.<sup>1</sup>
In 2017, West employees have worked diligently to help the communities in which we live and work. Through West without Borders, West's employee-led giving program, employees have raised more than $3 million for a variety of charities around the world.
Philanthropy is a cornerstone of our culture at West. It anchors our purpose of standing by the side of our customers to make a difference in our global community.
English
Chinese
